AIM ImmunoTech Inc. (AIM) Stock Price

AIMStock

$0.25−90.31%52W

Market Cap$7.73M

P/E—

PEG Ratio0.71

Div yield—

Beta1.31

AIM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-89.90%

Price vs S&P 500 (4W)4.58%

PEG Ratio0.71

VGM Score39.10

Book Value / Share (Quarterly)$0.26

P/TBV (Annual)2.71x

Revenue Growth (3Y)-14.54%

Cash Flow / Share (Quarterly)$-1.42

Price vs S&P 500 (YTD)-88.87%

Gross Margin (TTM)-29.79%

Net Profit Margin (TTM)-14123.40%

EPS (TTM)$-7.39

10-Day Avg Trading Volume1.03M

EPS Excl Extra (TTM)$-7.39

Revenue Growth (5Y)-11.60%

EPS (Annual)$-8.62

ROI (Annual)-283.00%

Gross Margin (Annual)-45.45%

Net Profit Margin (5Y Avg)-13669.23%

Cash / Share (Quarterly)$0.71

Revenue Growth QoQ (YoY)37.50%

ROA (Last FY)-241.40%

Revenue Growth TTM (YoY)-35.62%

EBITD / Share (TTM)$-4.06

ROE (5Y Avg)-92.13%

Operating Margin (TTM)-10926.60%

Cash Flow / Share (Annual)$-3.69

P/B Ratio3.73x

P/B Ratio (Quarterly)2.24x

Net Income / Employee (Annual)$-734,600

EV / Revenue (TTM)67.26x

Net Interest Coverage (TTM)-6.50x

ROA (TTM)-221.36%

EV / EBITDA (TTM)0.45x

EPS Incl Extra (Annual)$-8.62

Current Ratio (Annual)0.53x

Quick Ratio (Quarterly)0.96x

3-Month Avg Trading Volume19.56M

52-Week Price Return-90.31%

Revenue / Employee (TTM)$4,900

Tangible BV / Share (Quarterly)$0.06

P/S Ratio (Annual)90.05x

Asset Turnover (Annual)0.02x

52-Week High$2.89

Operating Margin (5Y Avg)-14153.95%

EPS Excl Extra (Annual)$-8.62

CapEx CAGR (5Y)-8.67%

Tangible BV CAGR (5Y)13.20%

26-Week Price Return-78.66%

Quick Ratio (Annual)0.49x

13-Week Price Return4.31%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.01x

Enterprise Value$6.32M

Revenue / Share Growth (5Y)60.55%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)34.84%

Revenue / Employee (Annual)$4,600

Inventory Turnover (Annual)1.67x

Pretax Margin (Annual)-15861.36%

Cash / Share (Annual)$0.99

3-Month Return Std Dev297.73%

Gross Margin (5Y Avg)-62.82%

Net Income / Employee (TTM)$-698,700

ROE (Last FY)-283.00%

Net Interest Coverage (Annual)-4.16x

EPS Basic Excl Extra (Annual)$-8.62

Receivables Turnover (TTM)12.18x

Total Debt / Equity (Quarterly)1.98x

EPS Incl Extra (TTM)$-7.39

Receivables Turnover (Annual)0.14x

ROI (TTM)-47.69%

P/S Ratio (TTM)84.30x

Pretax Margin (5Y Avg)-13669.23%

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$16.12

Price vs S&P 500 (52W)-108.62%

Year-to-Date Return-76.91%

5-Day Price Return8.59%

EPS Normalized (Annual)$-8.62

ROA (5Y Avg)-134.65%

Net Profit Margin (Annual)-15861.36%

Month-to-Date Return0.16%

Cash Flow / Share (TTM)$-0.42

EBITD / Share (Annual)$-7.18

Operating Margin (Annual)-13254.55%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-87.54%

LT Debt / Equity (Quarterly)0.10x

EPS Basic Excl Extra (TTM)$-7.39

P/TBV (Quarterly)10.29x

P/B Ratio (Annual)2.10x

Inventory Turnover (TTM)1.67x

Pretax Margin (TTM)-14123.40%

Book Value / Share (Annual)$20.82

Price vs S&P 500 (13W)1.52%

Beta1.31x

Revenue / Share (TTM)$0.02

ROE (TTM)-142.26%

52-Week Low$0.19

vGradeC

gGradeD

mGradeD

vgmGradeD

AIM Earnings Surprise History

Q2 25-3.68est. -7.99

Q3 25-1.57est. -0.98

Q4 25-0.44est. -0.94

Q1 26-0.69est. -0.37

Q2 26-0.43est. -0.12

AIM Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
AIMAIM ImmunoTech Inc.	C	D	D	$0.25
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About AIM ImmunoTech Inc.

AIM ImmunoTech is an immunotherapy company developing treatments for cancer, viral infections, and immune disorders. Its lead asset, Ampligen (rintatolimod), a novel double-stranded RNA therapeutic, is approved for commercial sale in Argentina for severe chronic fatigue syndrome. The company also markets Alferon N Injection (Interferon alfa).